CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Canakinumab

Last Updated: November 24, 2015
Result type: Reports
Project Number: SR0463-000
Product Line: Reimbursement Review

Generic Name: Canakinumab

Brand Name: Ilaris

Manufacturer: Novartis Pharmaceuticals Inc.

Therapeutic Area: Systemic Juvenile Idiopathic Arthritis

Indications: Systemic juvenile idiopathic arthritis

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: June 17, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions